Navigation Links
Novavax Prices Public Offering of Common Stock
Date:11/20/2009

age biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: our ability to satisfy all required closing conditions of the offering; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and other factors referenced herein. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... MENLO PARK, Calif. , April ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... Meeting of the American Association for Cancer Research ... its lead product candidate VAL-083 (dianhydrogalactitol) ...
(Date:4/20/2015)... , April 20, 2015  Ardelyx, Inc. ... focused on cardio-renal, gastrointestinal and metabolic diseases, today ... has joined the Company,s Board of Directors. Dr. ... board level experience, having built and led teams ... regulatory approval and into healthcare systems globally. ...
(Date:4/20/2015)... April 20, 2015  "Everybody is affected by cancer ... patients is frankly brutal. We,ve got to get away ... ward, or witnessed a loved one or friend battling ... the devastation chemotherapy and other treatments cause the human ... to give up and succumb to the disease. Dr. ...
(Date:4/20/2015)... Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical ... for the fourth quarter and full year ended December ... to the fourth quarter 2013) , Quarterly sales ... $22.9 million in the prior year period. Excluding revenue ... of $0.1 million in the fourth quarter of 2014 ...
Breaking Biology Technology:DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18
... first thing to do when draining a swamp is to ... an information swamp. Information not only needs to be better ... as its passed within an organization. IT shops are skilled ... and even the old, back office systems running on mainframes. ...
... Wis. Metavante Corporation , a Milwaukee-based provider ... Opsware System to automate its data center operations Tuesday. ... the tasks associated with managing its multi-data center information ... automation software has the opportunity to reduce complexity and ...
... make RFID an integral part of business and Wisconsin companies ... (radio frequency identification) tags and labels are small programmable carriers of ... an item. Also known as Smart Tags and Smart Labels, they ... Unlike bar codes, RFID tags and labels dont need to be ...
Cached Biology Technology:Draining the Information Swamp 2Draining the Information Swamp 3Bar Codes Have a New Best Friend RFID 2Bar Codes Have a New Best Friend RFID 3
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Society for Microbiology (ASM) Merck Irving S. Sigal Memorial ... Ph.D., co-director of the Infectious Disease Initiative at the ... in the Department of Medicine at Harvard Medical School. ... Sigal Memorial Award is presented in memory of Irving ...
... Society for Microbiology (ASM) USFCC/J. Roger Porter Award ... Professor Emeritus, Center for Ecology and Evolutionary Biology, ... by a scientist who has demonstrated the importance ... activities for a major resource used by the ...
... Berkeley In the famed Sharktooth Hill Bone Bed near ... weighing a pound each, intermixed with copious bones from extinct ... ground. Yet, new research by a team of paleontologists ... Columbia in Vancouver, Canada, and the University of Utah paints ...
Cached Biology News:Fossil bone bed helps reconstruct life along California's ancient coastline 2Fossil bone bed helps reconstruct life along California's ancient coastline 3Fossil bone bed helps reconstruct life along California's ancient coastline 4
... Disrupts biological cells for DNA ... 96 well plates (includes 96 well ... consistent lysis across the entire plate ... wells). Can be used for ...
Request Info...
GBL Antibody...
Dnase and Rnase free...
Biology Products: